The Motley Fool Investing Philosophy: We generally recommend investors buy shares of at least 25 stocks and hold them for at least 5 years. Learn More
| 1 Year | 5 Year | 5 Year Annualized | Since IPO | |
|---|---|---|---|---|
| TIL | -40.27% | N/A | N/A | -96% |
| S&P | +16.23% | +94.45% | +14.22% | +72% |
Instil Bio, Inc. is a clinical-stage biopharmaceutical company engaged in developing a cell therapy pipeline of autologous tumor infiltrating lymphocyte therapies for the treatment of patients with cancer. The company was founded in August 2018 and is headquartered in Dallas, TX.
A candidate that Instil Bio in-licensed this August is similar to a candidate that recently outperformed the world's top-selling cancer therapy.
| Q2 2025 | YOY Change | |
|---|---|---|
| Revenue | $0.00M | 0.0% |
| Gross Profit | -$0.01M | 98.8% |
| Market Cap | $136.64M | 104.2% |
| Market Cap / Employee | $9.76M | 0.0% |
| Employees | 14 | -71.4% |
| Net Income | -$21.39M | -43.4% |
| EBITDA | -$12.89M | -2.1% |
Currently no data to display
Currently no data to display.
Currently no data to display.
| Q2 2025 | YOY Change | |
|---|---|---|
| Net Cash | $7.84M | 15.6% |
| Inventory | 0 | 0.0% |
| Q2 2025 | YOY Change | |
|---|---|---|
| Long Term Debt | $84.43M | 0.6% |
| Short Term Debt | $0.46M | -72.7% |
| Q2 2025 | YOY Change | |
|---|---|---|
| Return On Assets | -32.18% | 1.9% |
| Return On Invested Capital | -34.24% | 10.4% |
| Q2 2025 | YOY Change | |
|---|---|---|
| Free Cash Flow | -$14.79M | -39.4% |
| Operating Free Cash Flow | -$14.79M | -39.4% |
| Metric | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | YoY Change |
|---|---|---|---|---|---|
| Price to Book | 2.25 | 0.71 | 0.67 | 0.94 | 189.91% |
| Price to Tangible Book Value | 2.25 | 0.71 | 0.67 | 0.94 | 189.91% |
| Enterprise Value to EBITDA | -38.87 | -8.98 | -6.83 | -10.11 | 3145.41% |
| Return on Equity | -36.6% | -37.5% | -44.5% | -51.7% | 6.34% |
| Total Debt | $85.35M | $86.89M | $86.67M | $84.88M | -0.86% |
Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.
